$EURK

Eureka Acquisition Corp (EURK): Entry into a Material Definitive Agreement

Eureka Acquisition Corp (EURK) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. false 0002000410 00-0000000 0002000410 2026-08-11 2026-08-11 0002000410 EURK:UnitsConsistingOfOneClassOrdinaryShare0.0001ParValueAndOneRightToAcquireOnefifthOfOneClassOrdinaryShareMember 2026-08-11 2026-08-11 0002000410 EURK:ClassOrdinarySharesParValue0.0001PerShareMember 2026-08

Original reporting
Published Aug 13, 2026, 8:57 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 13, 2026, 9:00 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefCorporate actions
Primary signal
$EURK
Neutral
medium confidence
Mentioned
$EURK
Relevance
6/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$EURKNeutralMed
01

Why it matters

The company extended the deadline by one month (Aug. 3 to Sept. 3, 2026) via a trust deposit funded by Marine Thinking and documented through a zero-interest extension promissory note with optional conversion into units.

02

Market read

This is a primary SEC filing detailing SPAC extension mechanics, reducing immediate deadline pressure while adding a small optional conversion/dilution pathway.

03

What to watch

Traders should watch whether Marine Thinking elects to convert the note into units, which could create incremental dilution and signal confidence in a forthcoming business combination.

Relevance 6/10Novelty 6/10Timing: filed after-hours on Aug. 13, 2026, for a deadline extension affecting the next business-combination window

Background

EURK is a SPAC with an initial business-combination deadline that can be extended by depositing monthly extension fees into its trust account.

Company-level read

Ticker impact

$EURKNeutralMedium confidence
Context

EURK disclosed a monthly extension fee deposit and issued an $8,253.03 zero-interest extension promissory note to extend its business-combination deadline to Sept. 3, 2026.

Expected impact

Near-term impact likely limited, but the extension reduces immediate liquidation risk while adding small conversion/dilution overhang if the note is converted.

Evidence & confidence

The 8-K is a primary disclosure of SPAC deadline extension mechanics (trust deposit, note terms, default/acceleration, and optional conversion). The dollar amount is small, so magnitude is likely modest, but the deadline extension is directly relevant to SPAC risk and investor expectations.

Market effects

Adds another data point on SPACs using monthly extension fees and note-based financing to bridge to later deal windows.

No clear regional spillover beyond US-listed SPAC investor sentiment.

Limited global relevance; primarily affects EURK’s capital structure and timeline.

Counterpoint

Because the extension fee and note principal are very small, the market may treat this as routine SPAC housekeeping rather than a meaningful catalyst.

Key entities

  • Eureka Acquisition Corp

    SPAC issuer filing the 8-K and extending its business-combination deadline via trust deposit and extension note.

  • Marine Thinking Inc.

    Canada-incorporated entity that funded the monthly extension fee and holds the extension note with optional conversion rights.

  • 17358750 Canada Inc.

    Wholly owned subsidiary of Eureka referenced in the business combination agreement.

Related articles

$MPLTMedAI 8/10

MapLight Raises $150 M PIPE To Fund CNS Pipeline

MapLight Therapeutics (MPLT) priced a $150 million PIPE, selling 9.2M shares at $11.38 and 4.0M pre-funded warrants at $11.3799, exercisable at $0.0001 with no expiration. Proceeds will fund CNS drug ML-007C-MA, including VISTA Phase 2 in Alzheimer’s disease psychosis and ZEPHYR-2 Phase 3 in schizophrenia. Closing expected Aug. 14, 2026.

$TSNMedAI 8/10

Tyson Foods will close or sell three US beef facilities as industry struggles

Tyson Foods said it will close or sell three US beef facilities, ending operations at Joslin, Illinois and Eagle Mountain, Utah, and pursuing the sale of Pasco, Washington, while shifting capacity to other sites. The move follows prior Tyson beef shutdowns and comes as a 75-year cattle supply trough drives losses. Tyson forecast a $500m to $650m adjusted beef operating loss for fiscal 2026.

$MVISMedAI 8/10

MicroVision, Inc.: MicroVision Announces Launch of Proposed Public Offering

MicroVision (NASDAQ:MVIS) said it has commenced a proposed public offering of units, each unit consisting of one share of common stock (or a pre-funded warrant in lieu) and one warrant to buy one share. MicroVision will sell the shares and warrants, with final terms to be set at pricing. Net proceeds are for general corporate purposes, including working capital and capex.

$ORCLMed

Oracle planning new round of layoffs in August 2026

Oracle plans another layoff round in August 2026, according to Business Insider citing internal documents and people familiar with the plans. It says some teams could face double-digit cuts, with managers asked to identify affected employees ahead of Sept. 1. Oracle previously cut 21,000 jobs and recorded $1.8B restructuring charges. Oracle is funding AI data centers with large debt and equity.

$TSNMed

Tyson Foods to close 2 facilities, pursue sale of another amid 'historic' cattle shortage

Tyson Foods said it will close its Joslin, Illinois beef plant and its Eagle Mountain, Utah case-ready facility, and is pursuing the sale of its Pasco, Washington beef facility, citing strategic changes to its beef network amid a “historic” cattle shortage. Tyson plans to shift capacity to Dakota City, Nebraska; Holcomb, Kansas; and Amarillo, Texas, and ramp a second shift in Amarillo, according to the company.

$KPTIHighAI 9/10

It's crunch time for Karyopharm as company faces potential default next month

Karyopharm Therapeutics reported Q2 results showing a $67 million loss and cash reserves of $65.4 million. A $15.8 million loan payment is due Sept. 10, and without financing or a waiver the company says it would breach a $10.0 million liquidity covenant and could default. It is negotiating with lenders and pursuing Xpovio label expansion; Q2 Xpovio sales were $30.8 million.